OTC Acetaminophen Label Guidance For Liver Warning Clarifies Ingredient Specifics
This article was originally published in The Tan Sheet
Executive Summary
FDA allows marketers of acetaminophen-containing OTC products to use an alternative liver warning, according to an updated guidance. The change from the draft, which aligns with a request by CHPA, separates maximum dosage for the ingredient from the dosage included in a certain product.
You may also be interested in...
High Acetaminophen Use In Pregnancy Linked To ADHD, Autism
Babies with cord blood biomarkers of acetaminophen on higher end of a scale are at three times risk of attention-deficit/hyperactivity disorder and almost four times at risk of autism spectrum disorder than babies with biomarkers on lower end, according to a JAMA study with 996 mother-infant pairs.
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.